

DESCRIPTION

Source Mouse myeloma cell line, NS0-derived human Common beta Chain protein
Trp17-Trp443, with a C-terminal 6-His tag
Accession # P32927-1

N-terminal Sequence Analysis Gly23 & Glu25

Predicted Molecular Mass 49 kDa

SPECIFICATIONS

SDS-PAGE 57-65 kDa, reducing conditions

Activity Measured by its binding ability in a functional ELISA.
Recombinant Human Common β Chain binds Recombinant Human GM-CSF (Catalog # 215-GM) in the presence of Recombinant Human GM-CSF R α (Catalog # 706-GR). The concentration of Recombinant Human Common β that produces 50% of the optimal binding response is 20-120 ng/mL.

Endotoxin Level <0.10 EU per 1 μ g of the protein by the LAL method.

Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Lyophilized from a 0.2 μ m filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 500 μ g/mL in PBS.


Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

- 12 months from date of receipt, ≤ -20 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.


DATA

Binding Activity



In the presence of Recombinant Human GM-CSF R α (Catalog # 706-GR), Recombinant Human Common Chain binds to Recombinant Human GM-CSF (Catalog # 215-GM) with an ED₅₀ of 20-120 ng/mL.

SDS-PAGE



2 μ g/lane of Recombinant Human Common β Chain was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® blue staining, showing bands at 57-65 kDa.

BACKGROUND

The common beta chain (beta c) is also known as GM-CSF R beta (granulocyte-macrophage colony stimulating factor receptor beta subunit), IL-3 R beta, and IL-5 R beta (gene name CSF2RB and designated CD131) (1, 2). It is a 58-61 kDa type I transmembrane protein that associates with the ligand-specific IL-3 R alpha on T cells and other cells, IL-5 R alpha on eosinophils or GM-CSF R alpha on myeloid cells, to form high affinity receptor complexes (1, 2). The 897 amino acid (aa) human beta c contains a 16 aa signal sequence, a 427 aa extracellular domain (ECD) with two fibronectin type III domains, a transmembrane sequence, and a 437 aa cytoplasmic domain (2, 3). Within the ECD, human beta c shares 57-68% aa sequence identity with mouse, rat, equine, porcine, bovine and canine beta c. Complexes of GM-CSF with its specific alpha subunit then bind preformed beta c dimers, creating 2:2:2 hexamers that can combine to a dodecamer (4:4:4) (3). Beta c association and dimerization via the dimerization of the hexamer to the dodecamer is essential for JAK2 activation via GM-CSF signaling which imparts growth and survival signals (3). Except for eosinophils, beta c is primarily involved when rapid production of leukocytes is needed, rather than for developmental or steady-state cell production (1). Beta c also associates with other receptors, forming heteroreceptor complexes that allow beta c complexes to influence the signaling pathways activated by the associated receptor (1). Beta c thus enhances angiogenesis (when associated with VEGF R2/KDR/Flt-1 or beta 1 integrins), cell protection (with Erythropoietin R), and synergistic growth of stem cells (with SCF R/c- kit) (4-9). Defective production of beta c in humans is a cause of pulmonary alveolar proteinosis (10).

References:

1. Lopez, A.F. *et al.* (2010) *IUBMB Life* **62**:509.
2. Hayashida, K. *et al.* (1990) *Proc. Natl. Acad. Sci. USA* **87**:9655.
3. Hansen, G. *et al.* (2008) *Cell* **134**:496.
4. Blake, T.J. *et al.* (2002) *J. Leukoc. Biol.* **72**:1246.
5. Brines, M. *et al.* (2004) *Proc. Natl. Acad. Sci. USA* **101**:14907.
6. Dentelli, P. *et al.* (2005) *Oncogene* **24**:6394.
7. Saulle, E. *et al.* (2009) *Br. J. Haematol.* **145**:399.
8. Lennartsson, J. *et al.* (2004) *J. Biol. Chem.* **279**:44544.
9. Uberti, B. *et al.* (2010) *Oncogene* **29**:6581.
10. Dirksen, U. *et al.* (1997) *J. Clin. Invest.* **100**:2211.